CompletedPhase 2

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

United States52 participantsStarted 2006-12

Plain-language summary

The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer * At least 1 measurable target lesion, as defined by RECIST Exclusion Criteria: * Thyroid lymphoma * Previous treatment with anti-angiogenesis agents * No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.

What they're measuring

Percentage of Participants With Objective Response (OR)

Timeframe: Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)

Trial details

NCT IDNCT00389441

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-09

Results submitted2013-09-24

View on ClinicalTrials.gov More Thyroid Neoplasms trials